Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lascufloxacin penetration into otorhinolaryngological tissues (LSPOT)
jRCTs031200219Completed
- Sponsor
- Kyorin Pharmaceutical
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lascufloxacin in pharyngitis, laryngitis, tonsillitis and 4 more, sponsored by Kyorin Pharmaceutical. Primary endpoints: Plasma concentration of lascufloxacin, Lascufloxacin concentration in each tissue and 1 more. Started Mar 2021; status: completed.
02
Drugs
lascufloxacin
03
Conditions
pharyngitislaryngitistonsillitisacute bronchitispneumonia
Beyond the preview
Go deeper on jRCTs031200219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200219.